XOMA Royalty (STU:X0M1) Debt-to-Asset : 0.50 (As of Jun. 2024)

View and export this data going back to 1986. Start your Free Trial

What is XOMA Royalty Debt-to-Asset?

XOMA Royalty's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €5.70 Mil. XOMA Royalty's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €107.57 Mil. XOMA Royalty's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €226.01 Mil. XOMA Royalty's debt to asset for the quarter that ended in Jun. 2024 was 0.50.

XOMA Royalty Debt-to-Asset Historical Data

The historical data trend for XOMA Royalty's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Debt-to-Asset Chart

XOMA Royalty Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.34

0.17

0.53

XOMA Royalty Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															-	-	0.53	0.55	0.50

Competitive Comparison of XOMA Royalty's Debt-to-Asset

For the Biotechnology subindustry, XOMA Royalty's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XOMA Royalty's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA Royalty's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where XOMA Royalty's Debt-to-Asset falls into.

XOMA Royalty Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

XOMA Royalty's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.132	+	108.988)	/	214.854
	=	0.53

XOMA Royalty's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.701	+	107.566)	/	226.007
	=	0.50

XOMA Royalty (STU:X0M1) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

XOMA Royalty Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (STU:X0M1) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA 0M26:UK

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines